Overall Survival Results with Daratumumab, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Phase 3 MAIA Study
Background of the study:
The primary analyses of the phase 3 ALCYONE, MAIA, and CASSIOPEIA studies established the superior clinical efficacy of daratumumab (DARA) in combination with standard-of-care regimens versus standard of care alone for patients with newly diagnosed multiple myeloma (NDMM). In ALCYONE, after longer follow-up, an overall survival (OS) benefit was observed; adding DARA to bortezomib, melphalan, and prednisone significantly reduced the risk of death by 40%. In the primary analysis of MAIA, DARA plus lenalidomide and dexamethasone (D-Rd) reduced the risk of disease progression or death by 44% versus lenalidomide and dexamethasone (Rd).
In this video:
Dr. Thierry Facon (Lille University Hospital, Lille, France) discusses the results of the MAIA study which compared the overall survival results in transplant-ineligible newly diagnosed multiple myeloma patients using daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone.
Conclusions:
After almost 5 years of follow-up, a significant and clinically meaningful OS improvement was demonstrated with the use of D-Rd versus Rd in patients with NDMM who are transplant ineligible, representing a 32% reduction in the risk of death. The significant PFS benefit of D-Rd versus Rd from the primary analysis (median follow-up, 28 months) was maintained, with a 47% reduction in risk of disease progression or death and a median PFS for D-Rd NR. The favorable benefit-risk profile observed supports the use of D-Rd in transplant-ineligible patients with NDMM. These results, together with the OS benefit observed in ALCYONE, support the use of frontline DARA-based combination regimens to maximize PFS for optimal long-term outcomes.
_______________
Improving Lives Through Research and Patient Care
In the United States, an estimated 32,270 new multiple myeloma cases will be diagnosed in 2021. 159,985 new myeloma cases are diagnosed yearly.
Founded in 1990, the International Myeloma Foundation (IMF) is the first and largest organization focusing specifically on multiple myeloma. The IMF’s reach extends to more than 525,000 members in 140 countries worldwide. The IMF is dedicated to improving the quality of lives of myeloma patients while working toward prevention and a cure through our four founding principles: Research, Education, Support, and Advocacy.
Subscribe to our channel: [ Ссылка ]
Visit our website at: [ Ссылка ]
Find us online:
Facebook: @myeloma | [ Ссылка ]
Twitter: @IMFMyeloma | [ Ссылка ]
Instagram: @imfmyeloma | [ Ссылка ]
LinkedIn: [ Ссылка ]
Support the IMF! [ Ссылка ]
Category
Nonprofits & Activism
License
Standard YouTube License
